Story perspectives

China's Biopharma Boom: 60% Surge Amid Market Volatility

8/11/2025

42 4

Summary

Story summary

The Chinese biopharma sector is booming, with the Hang Seng Biotech Index increasing by 60% in 2024-2025.
Allist Pharmaceuticals has achieved profitability post-IPO, aided by favorable STAR Market regulations.
Market volatility persists, exemplified by Cloudbreak Pharma's notable stock decline, indicating risks in speculative investments.
The STAR Market supports innovation, projecting China's biomedical sector to reach a value of 8 trillion yuan by 2030.

1 of 1

Story summary

The Chinese biopharma sector is booming, with the Hang Seng Biotech Index increasing by 60% in 2024-2025.
Allist Pharmaceuticals has achieved profitability post-IPO, aided by favorable STAR Market regulations.
Market volatility persists, exemplified by Cloudbreak Pharma's notable stock decline, indicating risks in speculative investments.
The STAR Market supports innovation, projecting China's biomedical sector to reach a value of 8 trillion yuan by 2030.